製品の概要

  • 製品名Anti-MLH3 antibody
    MLH3 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to MLH3
  • アプリケーション適用あり: WBmore details
  • 種交差性
    交差種: Human
    交差が予測される動物種: Mouse, Rat
  • 免疫原

    Recombinant fragment, corresponding to a region within amino acids 1-282 of Human MLH3 (AAI12168).

  • ポジティブ・コントロール
    • A549, HeLa, HepG2 and HCT116 whole cell lysates.

法規制情報

製品の特性

  • 製品の状態Liquid
  • 保存方法Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • バッファーpH: 7.00
    Preservative: 0.01% Thimerosal (merthiolate)
    Constituents: 20% Glycerol, 1.21% Tris, 0.75% Glycine
  • Concentration information loading...
  • 精製度Immunogen affinity purified
  • 特記事項(精製)ab111942 is purified by antigen-affinity chromatography.
  • ポリ/モノポリクローナル
  • アイソタイプIgG
  • 研究分野

アプリケーション

Our Abpromise guarantee covers the use of ab111942 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
WB 1/500 - 1/3000. Predicted molecular weight: 161 kDa.

ターゲット情報

  • 機能Probably involved in the repair of mismatches in DNA.
  • 組織特異性Ubiquitous.
  • 関連疾患Defects in MLH3 are the cause of hereditary non-polyposis colorectal cancer type 7 (HNPCC7) [MIM:614385]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.
    Defects in MLH3 are a cause of colorectal cancer (CRC) [MIM:114500].
  • 配列類似性Belongs to the DNA mismatch repair mutL/hexB family.
  • 細胞内局在Nucleus.
  • Information by UniProt
  • 参照データベース
  • 別名
    • DNA mismatch repair protein Mlh3 antibody
    • HNPCC 7 antibody
    • HNPCC antibody
    • HNPCC7 antibody
    • MGC138372 antibody
    • Mismatch repair gene MLH 3 antibody
    • Mismatch repair gene MLH3 antibody
    • MLH 3 antibody
    • MLH3 antibody
    • MLH3_HUMAN antibody
    • MutL homolog 3 (E. coli) antibody
    • MutL homolog 3 antibody
    • MutL protein homolog 3 antibody
    • S240II117 antibody
    see all

Anti-MLH3 antibody 画像

  • Anti-MLH3 antibody (ab111942) at 1/1000 dilution + HCT116 whole cell lysate at 30 µg

    Predicted band size : 161 kDa

Anti-MLH3 antibody (ab111942) 使用論文

ab111942 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab111942.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"